S J Horning

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484
    Sandra J Horning
    Stanford University, 875 Blake Wilbur Dr, Suite 2338, Stanford, CA 94305 5821, USA
    J Clin Oncol 22:3032-8. 2004
  2. pmc Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study
    Sandra J Horning
    Department of Medicine, Stanford University, CA, USA
    Blood 115:775-7; quiz 918. 2010
  3. doi Follow-up of adult cancer survivors: new paradigms for survivorship care planning
    Sandra J Horning
    Stanford University, Stanford, CA, USA
    Hematol Oncol Clin North Am 22:201-10, v. 2008
  4. ncbi High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial
    S J Horning
    Department of Medicine, Divisions of Bone Marrow Transplantation and Medical Oncology, Stanford University Medical Center, Stanford, CA, USA
    Blood 97:404-9. 2001
  5. ncbi Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab
    Sandra J Horning
    Stanford University, Stanford, CA 94305 5821, USA
    J Clin Oncol 23:712-9. 2005
  6. ncbi Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial
    Sandra J Horning
    Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, CA 94304, USA
    J Clin Oncol 20:630-7. 2002
  7. ncbi Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma
    L J Johnston
    Division of Bone Marrow Transplantation, Stanford University, California 94305, USA
    Biol Blood Marrow Transplant 6:555-62. 2000
  8. pmc Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial
    R H Advani
    Departments of Medicine Oncology, Stanford University Medical Center, 875 Blake Wilbur Drive, CC 2338, Stanford, CA 94305, USA
    Ann Oncol 24:1044-8. 2013
  9. ncbi Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease
    M J Stuart
    Division of Bone Marrow Transplantation, Stanford University Medical Center, California 94305 5623, USA
    Biol Blood Marrow Transplant 7:552-60. 2001
  10. ncbi Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation
    S J Horning
    Department of Medicine, Stanford University Medical Center, CA, USA
    J Clin Oncol 15:1736-44. 1997

Detail Information

Publications45

  1. ncbi Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484
    Sandra J Horning
    Stanford University, 875 Blake Wilbur Dr, Suite 2338, Stanford, CA 94305 5821, USA
    J Clin Oncol 22:3032-8. 2004
    ....
  2. pmc Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study
    Sandra J Horning
    Department of Medicine, Stanford University, CA, USA
    Blood 115:775-7; quiz 918. 2010
    ..This trial was registered at www.clinicaltrials.gov as #NCT00274924 [corrected]...
  3. doi Follow-up of adult cancer survivors: new paradigms for survivorship care planning
    Sandra J Horning
    Stanford University, Stanford, CA, USA
    Hematol Oncol Clin North Am 22:201-10, v. 2008
    ..Survivorship planning must become an integral part of every oncologist's education and practice...
  4. ncbi High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial
    S J Horning
    Department of Medicine, Divisions of Bone Marrow Transplantation and Medical Oncology, Stanford University Medical Center, Stanford, CA, USA
    Blood 97:404-9. 2001
    ....
  5. ncbi Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab
    Sandra J Horning
    Stanford University, Stanford, CA 94305 5821, USA
    J Clin Oncol 23:712-9. 2005
    ....
  6. ncbi Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial
    Sandra J Horning
    Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, CA 94304, USA
    J Clin Oncol 20:630-7. 2002
    ..To provide more mature data on the efficacy and complications of a brief, dose-intense chemotherapy regimen plus radiation therapy (RT) to bulky disease sites for locally extensive and advanced-stage Hodgkin's disease...
  7. ncbi Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma
    L J Johnston
    Division of Bone Marrow Transplantation, Stanford University, California 94305, USA
    Biol Blood Marrow Transplant 6:555-62. 2000
    ..We conclude that HDSC/AHCT in refractory/recurrent NHL is associated with considerable acute and chronic toxicities. Given the toxicity profile, efficacy data were not sufficiently promising to warrant further study...
  8. pmc Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial
    R H Advani
    Departments of Medicine Oncology, Stanford University Medical Center, 875 Blake Wilbur Drive, CC 2338, Stanford, CA 94305, USA
    Ann Oncol 24:1044-8. 2013
    ..Stanford V chemotherapy was administered for 8 weeks followed by radiation therapy (RT) 30 Gy to involved fields (IF). Freedom from progression (FFP), disease-specific survival (DSS) and overall survival (OS) were estimated...
  9. ncbi Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease
    M J Stuart
    Division of Bone Marrow Transplantation, Stanford University Medical Center, California 94305 5623, USA
    Biol Blood Marrow Transplant 7:552-60. 2001
    ..This regimen demonstrated survival rates similar to those of historical studies that used the CBV regimen. However, the incidence of interstitial pneumonitis was in excess of expected...
  10. ncbi Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation
    S J Horning
    Department of Medicine, Stanford University Medical Center, CA, USA
    J Clin Oncol 15:1736-44. 1997
    ..The purpose of this study is to determine if VBM and regional radiotherapy can substitute for extended-field radiotherapy in favorable clinical stage (CS) I and II HD...
  11. ncbi Autologous hematopoietic cell transplantation in non-Hodgkin's lymphoma
    L J Johnston
    Division of Bone Marrow Transplantation, Stanford University Medical Center, California, USA
    Hematol Oncol Clin North Am 13:889-918. 1999
    ..A large number of NHL patients succumb to their disease, so it is hoped that alternate therapies, such as cytokines, monoclonal antibodies, and vaccines, may improve the results of HDT...
  12. ncbi Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
    Steven M Horwitz
    Division of Oncology, Stanford University Medical Center, Ste 202, 1000 Welch Rd, Palo Alto, CA 94304, USA
    Blood 103:777-83. 2004
    ..Rituximab after HDT and HCT is feasible, and these phase 2 data support the current US Intergroup phase 3 trial in recurrent/refractory diffuse large cell lymphoma...
  13. ncbi Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492
    S J Horning
    Department of Medicine, Stanford University Medical Center, Stanford, CA, USA
    J Clin Oncol 18:972-80. 2000
    ..This study was performed, in a multi-institutional setting, to evaluate the efficacy and feasibility of the Stanford V chemotherapy regimen plus radiotherapy to bulky Hodgkin's disease sites...
  14. ncbi High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
    Lisa Y Law
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 12:703-11. 2006
    ..Patients who had required >3 previous chemotherapy regimens before HCT had an increased probability of relapse. CBV is an effective preparative regimen for patients with aggressive NHL who undergo allogeneic HCT...
  15. ncbi Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial
    Bradley C Ekstrand
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94304, USA
    Blood 101:4285-9. 2003
    ..Further clinical trials are warranted to determine the optimal dosing schedule of rituximab, the potential for combination treatment, and the possible relationship of rituximab treatment to the development of LCL...
  16. doi Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin
    Olga K Weinberg
    Department of Pathology, Stanford University Medical Center, Stanford Comprehensive Cancer Center, Stanford, CA 94305, USA
    Am J Surg Pathol 33:591-8. 2009
    ..019) and disease-specific survival (P=0.006) in comparison with the t(14;18)-negative group. In low stage FL, the status of t(14;18) seems to be more predictive of outcome than origin from an extranodal versus nodal site...
  17. pmc Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience
    Andy I Chen
    Stanford University Medical Center, Division of Blood and Marrow Transplantation, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 14:741-7. 2008
    ....
  18. ncbi Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease
    Ranjana Advani
    Stanford University Comprehensive Cancer Center, Stanford, CA 94305, USA
    J Clin Oncol 25:3902-7. 2007
    ..To correlate [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) status after chemotherapy, but before radiation, with outcome in patients treated with the Stanford V regimen...
  19. ncbi Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine
    Ranjana Advani
    Stanford University Medical Center, Stanford, CA 94305 5821, USA
    Leuk Lymphoma 48:521-5. 2007
    ..By interrupting T-cell activation, CsA may alter the immune dysregulation that characterizes AILT. The efficacy of CsA is being explored in patients with recurrent AILT in a prospective trial (ECOG 2402)...
  20. pmc Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma
    Wen Kai Weng
    Division of Blood and Marrow Transplantation, 300 Pasteur Dr, Rm H3249, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Clin Oncol 28:279-84. 2010
    ..In the current report, we determine whether FcgammaR polymorphisms are correlated with clinical outcomes in 33 patients with B-cell non-Hodgkin's lymphoma who received post-transplantation rituximab...
  21. ncbi Management of advanced stage Hodgkin lymphoma
    Ranjana Advani
    Stanford University Medical Center, Stanford, California 94305, USA
    J Natl Compr Canc Netw 4:241-7. 2006
    ....
  22. ncbi Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease
    Paul A Heidenreich
    Department of Medicine, Division of Cardiology, Stanford University Medical Center, Stanford, CA, USA
    J Clin Oncol 25:43-9. 2007
    ..The objective of this study was to evaluate whether stress imaging can identify severe, unsuspected coronary stenoses in patients who had prior mediastinal irradiation for Hodgkin's disease...
  23. pmc Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma
    Sally Arai
    Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 16:1145-54. 2010
    ..This new transplant regimen for HL resulted in decreased BCNU toxicity with encouraging FFP and OS. A prospective, risk-modeled comparison of this new combination with other conditioning regimens is warranted...
  24. ncbi Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy
    Ranjana Advani
    Division of Oncology, Department of Medicine, Stanford University Medical Center, 875 Blake Wilber Drive, Stanford, CA 94305, USA
    J Clin Oncol 22:1454-9. 2004
    ....
  25. doi Utility of influenza vaccination for oncology patients
    Daniel A Pollyea
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    J Clin Oncol 28:2481-90. 2010
    ....
  26. pmc Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic in
    Ranjana H Advani
    Stanford University, Stanford, CA 94305, USA
    Br J Haematol 151:143-51. 2010
    ..The prognostic discrimination provided by the E-IPI for low and low-intermediate elderly DLBCL patients needs validation by other datasets...
  27. ncbi Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis
    Kristen N Ganjoo
    Department of Medicine Oncology, Stanford University, CA, USA
    Leuk Lymphoma 47:998-1005. 2006
    ..In this patient population, treatment with RA-CHOP did not result in any episodes of grade 3 or 4 proteinuria, heart failure or hemorrhage. The RA-CHOP combination was generally well tolerated and safe...
  28. ncbi Rituximab in stem cell transplantation for aggressive lymphoma
    Steven M Horwitz
    Oncology and Bone Marrow Transplantation, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Curr Hematol Rep 3:227-9. 2004
  29. ncbi Future directions in radioimmunotherapy for B-cell lymphoma
    Sandra J Horning
    Division of Oncology, Stanford University School of Medicine, Palo Alto, CA 94304, USA
    Semin Oncol 30:29-34. 2003
    ....
  30. ncbi Lymphocyte predominant Hodgkin's disease
    Bradley C Ekstrand
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, 1000 Welch Road, Suite 202, Palo Alto, CA 94304, USA
    Curr Oncol Rep 4:424-33. 2002
    ..Recent insights into the molecular pathogenesis of LPHD and the development of novel targeted therapies promise to improve future treatment...
  31. ncbi Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab
    Y Natkunam
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Clin Lymphoma 2:185-7. 2001
    ..We present an unusual case of a 30-year-old man with recurrent TCRBCL arising from lymphocyte-predominant Hodgkin's disease with remarkable response to treatment with the anti-CD20 antibody, rituximab...
  32. ncbi Hodgkin's disease
    Bradley C Ekstrand
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Blood Rev 16:111-7. 2002
    ..Patients who relapse now have a more favorable prognosis with the availability of active salvage regimens, autologous stem cell transplantation, and novel biologic agents...
  33. ncbi Lymphocyte predominant Hodgkin's disease: more patience than patients
    Bradley C Ekstrand
    Department of Medicine, Stanford University School of Medicine, California 94304, USA
    Cancer J 8:367-8. 2002
  34. ncbi Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease
    Holbrook Kohrt
    Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA
    Oncol Res 18:287-92. 2009
    ..Our observation challenges prior belief that patients with HD remain immunodeficient following therapy and argues that the clinical significance of the EBV-specific immune response in EBV-negative HD should be further investigated...
  35. ncbi Something old, something few, something subjective, something déjà vu
    Sandra J Horning
    J Clin Oncol 21:1-2. 2003
  36. ncbi Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group
    Ralph M Meyer
    Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada
    J Clin Oncol 23:4634-42. 2005
    ..We report results of a randomized trial comparing ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy alone with treatment that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma...
  37. ncbi Revised response criteria for malignant lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    J Clin Oncol 25:579-86. 2007
    ..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies...
  38. pmc Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
    Jane N Winter
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Blood 107:4207-13. 2006
    ..Our finding that Bcl-6(+) cases did not benefit from the addition of R to CHOP requires independent confirmation...
  39. ncbi Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    Thomas M Habermann
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 24:3121-7. 2006
    ....
  40. ncbi FDG-PET lymphoma demonstration project invitational workshop
    Gary J Kelloff
    National Institutes of Health NIH National Cancer Institute NCI Division of Cancer Treatment and Diagnosis DCTD Cancer Imaging Program, Bethesda, MD, USA
    Acad Radiol 14:330-9. 2007
    ....
  41. ncbi Optimizing rituximab in B-cell lymphoma
    Sandra J Horning
    J Clin Oncol 23:1056-8. 2005
  42. ncbi Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop
    Robert C Bast
    M D Anderson Cancer Center, Houston, TX, USA
    Gynecol Oncol 107:173-6. 2007
    ....
  43. ncbi Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497
    Timothy M Kuzel
    Feinberg School of Medicine Northwestern University, Chicago, IL 60611, USA
    Leuk Lymphoma 48:2397-402. 2007
    ..Toxicities were generally grade I - II and transient but 1 patient experienced a fatal thrombo-embolism. Therapy with DD is tolerable and modest efficacy was observed in SLL subtype. Measured IL-2R status did not correlate with efficacy...
  44. ncbi Burkitt's lymphoma--the message from microarrays
    Nancy Lee Harris
    N Engl J Med 354:2495-8. 2006
  45. ncbi Follicular lymphoma, survival, and rituximab: is it time to declare victory?
    Sandra J Horning
    J Clin Oncol 26:4537-8. 2008